CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
- DOI
- 10.1038/s41591-023-02404-6
- Published
- 2023 Jul
- Container
- Nature medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-023-02404-6,
title = {CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.},
author = {Park JH and Nath K and Devlin SM and Sauter CS and Palomba ML and Shah G and Dahi P and Lin RJ and Scordo M and Perales MA and Shouval R and Tomas AA and Cathcart E and Mead E and Santomasso B and Holodny A and Brentjens RJ and Riviere I and Sadelain M},
year = {2023},
journal = {Nature medicine},
doi = {10.1038/s41591-023-02404-6},
url = {https://doi.org/10.1038/s41591-023-02404-6}
}RIS
TY - JOUR TI - CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. AU - Park JH AU - Nath K AU - Devlin SM AU - Sauter CS AU - Palomba ML AU - Shah G AU - Dahi P AU - Lin RJ AU - Scordo M AU - Perales MA AU - Shouval R AU - Tomas AA AU - Cathcart E AU - Mead E AU - Santomasso B AU - Holodny A AU - Brentjens RJ AU - Riviere I AU - Sadelain M PY - 2023 JO - Nature medicine DO - 10.1038/s41591-023-02404-6 UR - https://doi.org/10.1038/s41591-023-02404-6 ER -
APA
JH, P., K, N., SM, D., CS, S., ML, P., G, S., P, D., RJ, L., M, S., MA, P., R, S., AA, T., E, C., E, M., B, S., A, H., RJ, B., I, R., & M, S. (2023). CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.. Nature medicine. https://doi.org/10.1038/s41591-023-02404-6
Source records
- pubmed · retrieved 2026-09-27T00:43:14.190Z